US42254E1047 - Common Stock
NASDAQ:HSCS (9/30/2022, 7:25:59 PM)-0.01 (-0.84%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Equipment & Supplies|
|Earnings (Last)||09-23 2022-09-23/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||10.91%||Inst Owners||N/A|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Heart Test Laboratories, Inc. is a medical technology company focused on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 12 full-time employees. The company went IPO on 2022-06-15. The Company’s product candidate, the MyoVista wavECG, or the MyoVista, is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista is a 12-lead resting ECG device that features its algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates. The MyoVista uses electrical information from the heart captured during a standard resting 12-lead ECG test as inputs to an artificial intelligence-based algorithm. The MyoVista detects whether a patient is negative or positive for abnormally slow left ventricular diastolic relaxation rates.
HEART TEST LABORATORIES INC
550 Reserve St, Suite 360
Patent continues to strengthen and expand IP portfolio...
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission...
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company...
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday!
Here you can normally see the latest stock twits on HSCS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.